Holen Sie sich die Stockscreener-App
6.81
0.15%
-0.01
Schlusskurs vom Vortag:
$6.82
Offen:
$6.94
24-Stunden-Volumen:
204.73K
Relative Volume:
0.66
Marktkapitalisierung:
$384.32M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-72.89M
KGV:
-2.814
EPS:
-2.42
Netto-Cashflow:
$-68.47M
1W Leistung:
-3.54%
1M Leistung:
-10.04%
6M Leistung:
-42.92%
1J Leistung:
-47.53%
1-Tages-Spanne:
$6.80
$7.02
1-Wochen-Bereich:
$6.77
$7.30
52-Wochen-Spanne:
$6.64
$16.90
Astria Therapeutics Inc Stock (ATXS) Company Profile
Firmenname
Astria Therapeutics Inc
Sektor
Branche
Telefon
617-349-1971
Adresse
22 BOSTON WHARF ROAD, BOSTON
Vergleichen Sie ATXS mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ATXS
Astria Therapeutics Inc
|
6.81 | 384.32M | 0 | -72.89M | -68.47M | -2.42 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.24 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
700.33 | 76.56B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
644.48 | 39.16B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
250.59 | 32.44B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
120.01 | 28.77B | 3.30B | -501.07M | 1.03B | -2.1146 |
Astria Therapeutics Inc Stock (ATXS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-01-31 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2024-07-29 | Eingeleitet | TD Cowen | Buy |
| 2023-03-28 | Eingeleitet | Evercore ISI | Outperform |
Astria Therapeutics Inc Aktie (ATXS) Neueste Nachrichten
When the Price of (ATXS) Talks, People Listen - Stock Traders Daily
Can Astria's New HAE Drug Data Transform Treatment? Key Findings Revealed at Major Medical Congress - StockTitan
Astria Therapeutics (NASDAQ:ATXS) Shares Pass Below Fifty Day Moving Average – What’s Next? - Defense World
Astria Therapeutics: A High-Conviction Bet On HAE - Seeking Alpha
Astria Therapeutics, Inc. (NASDAQ:ATXS) Receives $25.67 Consensus Price Target from Analysts - Defense World
How to Take Advantage of moves in (ATXS) - Stock Traders Daily
Astria Therapeutics, Inc. (NASDAQ:ATXS) Receives $25.67 Consensus Target Price from Brokerages - MarketBeat
Astria Therapeutics (NASDAQ:ATXS) Stock Rating Upgraded by Citizens Jmp - MarketBeat
Astria Therapeutics (NASDAQ:ATXS) Now Covered by Analysts at JMP Securities - MarketBeat
Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
Angioedema Pipeline 2024: Therapies Under Investigation, - openPR
Astria Therapeutics to Present at Upcoming Oppenheimer 35th Annual Healthcare Life Sciences Conference - sharewise
Astria wins new Outperform rating at JMP on drug technology - MSN
Astria Therapeutics, Inc. (NASDAQ:ATXS) Short Interest Update - MarketBeat
Astria Therapeutics to Present at Upcoming Western Society of Allergy, Asthma & Immunology Annual Scientific Session - Business Wire
Breakthrough HAE Treatment Data: Navenibart Shows Rapid Quality of Life Improvements in Clinical Trial - StockTitan
JMP Securities starts Astria Therapeutics stock at Market Outperform - MSN
JMP Securities Initiates Coverage of Astria Therapeutics (ATXS) with Market Outperform Recommendation - MSN
Astria Therapeutics' Shares Rise After JMP Securities Initiates Coverage With Outperform Rating - Marketscreener.com
Astria stock wins new Outperform at JMP (ATXS:NASDAQ) - Seeking Alpha
JMP Securities starts Astria Therapeutics stock at Market Outperform By Investing.com - Investing.com Canada
JMP Securities Initiates Astria Therapeutics at Outperform -January 31, 2025 at 08:17 am EST - Marketscreener.com
JMP Securities starts Astria Therapeutics stock with $26 target By Investing.com - Investing.com Canada
JPMorgan Chase & Co. Increases Position in Astria Therapeutics, Inc. (NASDAQ:ATXS) - Defense World
What To Expect From Astria Therapeutics In Q4 - RTTNews
Astria Therapeutics (NASDAQ:ATXS) Earns “Buy” Rating from HC Wainwright - Defense World
HC Wainwright Reaffirms "Buy" Rating for Astria Therapeutics (NASDAQ:ATXS) - MarketBeat
H.C. Wainwright sets $16 target on Astria Therapeutics stock - MSN
Astria Therapeutics Announces Initiation of Phase 1a Trial of STAR-0310, a Potential Best-in-Class Monoclonal Antibody OX40 Antagonist for the Treatment of Atopic Dermatitis - Business Wire
Where are the Opportunities in (ATXS) - Stock Traders Daily
Astria Therapeutics, Inc. (NASDAQ:ATXS) Sees Large Increase in Short Interest - MarketBeat
Astria Therapeutics, Inc. (NASDAQ:ATXS) Receives $25.60 Consensus Price Target from Brokerages - Defense World
HC Wainwright Reaffirms “Buy” Rating for Astria Therapeutics (NASDAQ:ATXS) - Defense World
Barclays PLC Has $1.02 Million Stake in Astria Therapeutics, Inc. (NASDAQ:ATXS) - Defense World
Astria Therapeutics (NASDAQ:ATXS) Receives Buy Rating from HC Wainwright - MarketBeat
Astria Therapeutics plans phase 3 trial for HAE drug - Investing.com
Astria Therapeutics Announces Design of ALPHA-ORBIT Pivotal Phase 3 Trial of Navenibart in HAE - Business Wire
Astria Therapeutics, Inc. (NASDAQ:ATXS) Receives Average Rating of "Buy" from Analysts - MarketBeat
Jane Street Group LLC Has $404,000 Position in Astria Therapeutics, Inc. (NASDAQ:ATXS) - Defense World
Jane Street Group LLC Cuts Stock Position in Astria Therapeutics, Inc. (NASDAQ:ATXS) - MarketBeat
Astria Therapeutics Awards Stock Options to New Employees Under Inducement Plan | ATXS Stock News - StockTitan
Geode Capital Management LLC Trims Stake in Astria Therapeutics, Inc. (NASDAQ:ATXS) - Defense World
Geode Capital Management LLC Has $10.50 Million Position in Astria Therapeutics, Inc. (NASDAQ:ATXS) - MarketBeat
Barclays PLC Boosts Stake in Astria Therapeutics, Inc. (NASDAQ:ATXS) - Defense World
Astria Therapeutics, Inc. (NASDAQ:ATXS) Sees Large Decrease in Short Interest - MarketBeat
Finanzdaten der Astria Therapeutics Inc-Aktie (ATXS)
Umsatz
Nettogewinn
Free Cashflow
ENV
Astria Therapeutics Inc-Aktie (ATXS) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Morabito Christopher | Chief Medical Officer |
Apr 01 '24 |
Sale |
13.59 |
10,000 |
135,939 |
0 |
0.27%
3.05%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):